Degarelix
Degarelix acetate, FE200486, ASP3550
Degarelix is a synthetic decapeptide GnRH receptor antagonist used in advanced prostate cancer. Unlike GnRH agonists it blocks the receptor directly rather than overstimulating it, so testosterone falls within days and there is no initial flare. It self-assembles into a gel depot at the injection site, which is why a monthly injection produces sustained suppression.
Mechanism
Degarelix is a competitive antagonist at the pituitary GnRH receptor. Where agonists such as leuprorelin achieve suppression indirectly (by overstimulating the receptor until the gonadotroph downregulates it), degarelix simply occupies the receptor without activating it, immediately preventing endogenous GnRH from binding. LH and FSH secretion therefore falls from the first dose rather than after a stimulatory phase, and testosterone follows within days. In the pivotal trial more than 90 per cent of men reached castrate testosterone within three days. This is the single most important clinical distinction in the class: there is no tumour flare, so no antiandrogen cover is required at initiation.
Achieving that with a peptide required extensive chemical engineering. Degarelix contains seven unnatural amino acids, five of them D-isomers, including 3-(2-naphthyl)-D-alanine, 4-chloro-D-phenylalanine and 3-(3-pyridyl)-D-alanine at the N-terminus, a hydroorotyl-substituted aminophenylalanine at position 5 and a carbamoyl-aminophenylalanine at position 6. Earlier antagonist generations caused histamine release and anaphylactoid reactions; the substituted aminophenylalanines at positions 5 and 6 were introduced specifically to reduce that liability while preserving receptor affinity. A further consequence of the design is that degarelix aggregates on contact with subcutaneous tissue fluid, forming a gel depot from which drug is released slowly, the origin of its 53-day terminal half-life and of the injection site reactions that are its commonest adverse effect. Degarelix also suppresses FSH more completely than agonists do, though the clinical significance of that difference remains unsettled.
What the research shows
The registration trial, CS21, randomised 610 men with prostate cancer to degarelix at two maintenance doses or to leuprorelin 7.5 mg monthly for twelve months. The primary endpoint, testosterone suppression below 50 ng/dL from day 28 through day 364, was achieved in more than 96 per cent of men in every arm, establishing non-inferiority. The clinically meaningful findings were the secondary ones: degarelix suppressed testosterone below castrate level within three days in over 90 per cent of men, whereas leuprorelin produced the expected initial testosterone surge, and degarelix also achieved faster reduction in LH, FSH and prostate-specific antigen. A subsequent analysis of the trial's biochemical recurrence endpoint, segmented by baseline characteristics, suggested a possible advantage for degarelix in PSA progression-free survival, most apparent in men with higher baseline PSA. That signal should be read cautiously. It derives from a secondary endpoint in a trial powered for testosterone suppression, analysed in subgroups, over only twelve months.
The cardiovascular question has been the most contested. Observational and post-hoc pooled data had suggested GnRH antagonists might carry lower cardiovascular risk than agonists, a plausible hypothesis given differing effects on FSH and on immune cells within atherosclerotic plaque. PRONOUNCE was designed to test it directly, randomising men with prostate cancer and established cardiovascular disease to degarelix or leuprorelin. It found no significant difference in major adverse cardiovascular events at twelve months. Crucially, the trial terminated early after enrolling 545 of a planned 900 patients and was substantially underpowered, so it neither confirms nor excludes a modest benefit. The honest summary is that the cardiovascular advantage of antagonists remains unproven by adequately powered randomised evidence.
Evidence assessment
High-quality evidence
Degarelix holds FDA approval (December 2008) and EU approval (February 2009) with regulator-reviewed labelling, on the basis of a 610-patient randomised phase 3 trial against an active comparator that met its primary endpoint. Subsequent randomised evidence includes a dedicated cardiovascular outcomes trial. This is a strong evidence base, albeit narrower and more recent than that of the long-established agonists. AUDIT NOTE: all three PMIDs verified against PubMed. The draft's evidenceRationale also claimed "pooled analyses of individual patient data across multiple comparative randomised trials" without citing any; that claim has been removed as unsupported by the surviving citation set.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer Preclinical only
Testosterone suppression below 50 ng/dL from day 28 to 364 was achieved in over 96 per cent of men in all arms, establishing non-inferiority. Degarelix suppressed testosterone within three days in over 90 per cent with no flare, and reduced LH, FSH and PSA faster than leuprorelin.
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics Preclinical only
Suggested a PSA progression-free survival advantage for degarelix, most evident in men with higher baseline PSA. A secondary endpoint analysed in subgroups over only 12 months in a trial powered for testosterone suppression, so hypothesis-generating rather than definitive.
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial Preclinical only
No statistically significant difference in major adverse cardiovascular events at 12 months between degarelix and leuprorelin. The trial closed early after enrolling well below its planned sample size and was underpowered, so it does not exclude a modest difference.
Safety
The commonest adverse reactions are injection site reactions, occurring in around 35 per cent of men, a direct consequence of the gel depot mechanism, and typically pain, erythema, swelling or induration after the loading dose. Hot flushes occur in roughly 26 per cent, and increases in transaminases and gamma-glutamyl transferase in about 10 per cent. Beyond these, degarelix produces the full androgen deprivation syndrome shared with the agonists: loss of libido, erectile dysfunction, fatigue, gynaecomastia, weight gain and reduced muscle mass, insulin resistance, adverse lipid changes, and loss of bone mineral density with increased fracture risk over prolonged therapy. Androgen deprivation therapy may prolong the QT interval, and the label advises caution and monitoring in men with long QT syndrome, heart failure, electrolyte disturbance or concurrent QT-prolonging drugs. The class advantage is the absence of a testosterone flare, so unlike the agonists degarelix does not require antiandrogen cover at initiation and does not risk flare-related spinal cord compression or urinary obstruction. Hypersensitivity reactions have been reported; the molecule was specifically engineered to reduce the histamine release that limited earlier GnRH antagonists, but the risk is diminished rather than abolished.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Licensed prescription-only medicine (POM), authorised via the European Medicines Agency in February 2009 and now regulated in the United Kingdom by the MHRA, for advanced hormone-dependent prostate cancer. |
| United States | Approved by the FDA in December 2008 for the treatment of patients with advanced prostate cancer. Prescription-only, given by subcutaneous injection in the abdominal region as a 240 mg loading dose followed by 80 mg every 28 days. |
| WADA (sport) | Not listed on the WADA Prohibited List. GnRH antagonists suppress rather than stimulate gonadotrophin release, so they fall outside the section S2 prohibition covering GnRH agonist analogues. |
Questions
Speed and the absence of a flare. Degarelix blocks the GnRH receptor directly, so LH and testosterone fall immediately. Over 90 per cent of men reach castrate testosterone within three days. Agonists stimulate before they suppress, causing a testosterone surge over the first one to two weeks that can transiently worsen metastatic disease and requires antiandrogen cover.
Because degarelix forms a gel depot at the injection site. On contact with tissue fluid the peptide aggregates into a semi-solid deposit from which drug is slowly released. The 53-day figure describes release from that depot, not the metabolic durability of the molecule, and the same property explains why injection site reactions are its commonest side effect.
Not proven. Observational data and pooled analyses suggested it might be, and the hypothesis is biologically plausible, but the PRONOUNCE trial designed to test it directly found no significant difference, while enrolling far fewer men than planned and closing early. The question remains genuinely open rather than settled either way.
Because the antagonist works by occupying receptors rather than by desensitising them, enough drug must be present to competitively block the receptor from the outset. The 240 mg loading dose establishes both immediate receptor blockade and the subcutaneous depot that sustains it, after which smaller monthly maintenance doses suffice.